162 related articles for article (PubMed ID: 35646536)
21. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
[TBL] [Abstract][Full Text] [Related]
22. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
23. Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.
Shanchun H; You P; Sujuan N; Xuebing Z; Yijie B; Xiaohui X; Jianming H; La N; Zhehui B; Qi L; Wulong J
Arch Oral Biol; 2023 Mar; 147():105637. PubMed ID: 36738487
[TBL] [Abstract][Full Text] [Related]
24. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
25. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
26. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
[TBL] [Abstract][Full Text] [Related]
27. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck.
Mandal M; Younes M; Swan EA; Jasser SA; Doan D; Yigitbasi O; McMurphey A; Ludwick J; El-Naggar AK; Bucana C; Mills GB; Myers JN
Oral Oncol; 2006 Apr; 42(4):430-9. PubMed ID: 16442835
[TBL] [Abstract][Full Text] [Related]
28. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
29. C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma.
Di JX; Zhang HY
Anticancer Drugs; 2019 Sep; 30(8):846-853. PubMed ID: 30870229
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance and biological functions of chemokine CXCL3 in head and neck squamous cell carcinoma.
Guan J; Weng J; Ren Q; Zhang C; Hu L; Deng W; Lu S; Dong X; Li W; Li Y; Wang W
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34870709
[TBL] [Abstract][Full Text] [Related]
31. Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets.
Shen Y; Liu J; Zhang L; Dong S; Zhang J; Liu Y; Zhou H; Dong W
Biomed Res Int; 2019; 2019():7376034. PubMed ID: 31485443
[TBL] [Abstract][Full Text] [Related]
32. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
Qi Z; Qiu Y; Wang Z; Zhang H; Lu L; Liu Y; Mathes D; Pomfret EA; Gao D; Lu SL; Wang Z
Mol Oncol; 2021 Apr; 15(4):1054-1068. PubMed ID: 33540470
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
34. The effect of fascin 1 inhibition on head and neck squamous cell carcinoma cells.
Wahab A; Hyytiäinen A; Wahbi W; Tuomainen K; Tervo S; Conesa-Zamora P; Jauhiainen L; Mäkinen LK; Paavonen T; Toppila-Salmi S; Salem A; Almangush A; Salo T; Al-Samadi A
Eur J Oral Sci; 2021 Dec; 129(6):e12819. PubMed ID: 34346523
[TBL] [Abstract][Full Text] [Related]
35. Rh type C-glycoprotein functions as a novel tumor suppressor gene by inhibiting tumorigenicity and metastasis in head and neck squamous cell carcinoma.
Xu W; Zou H; Wei Z; Song C; Tang C; Yin X; Wang Y; Han S; Cai Y; Han W
Aging (Albany NY); 2019 Jun; 11(11):3601-3623. PubMed ID: 31170090
[TBL] [Abstract][Full Text] [Related]
36. HSPA5, as a ferroptosis regulator, may serve as a potential therapeutic for head and neck squamous cell carcinoma.
Li J; Xiao W; Wei W; Wu M; Xiong K; Lyu J; Li Y
Mol Immunol; 2023 Jun; 158():79-90. PubMed ID: 37172353
[TBL] [Abstract][Full Text] [Related]
37. Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines.
Atri S; Nasoohi N; Hodjat M
Curr Mol Pharmacol; 2021; 14(1):60-67. PubMed ID: 32394848
[TBL] [Abstract][Full Text] [Related]
38. miR-762 Promotes Malignant Development of Head and Neck Squamous Cell Carcinoma by Targeting PHLPP2 and FOXO4.
Chen S; Zhang JY; Sun LS; Li XF; Bai JY; Zhang HY; Li TJ
Onco Targets Ther; 2019; 12():11425-11436. PubMed ID: 31920332
[TBL] [Abstract][Full Text] [Related]
39. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
[TBL] [Abstract][Full Text] [Related]
40. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
